Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models

DMM Disease Models and Mechanisms

Volumn 9, Issue 12, 2016, Pages 1461-1471

  Céspedes, María Virtudes ^a   Guillén, María José ^b   López Casas, Pedro Pablo ^c   Sarno, Francesca ^c   Gallardo, Alberto ^a   Álamo, Patricia ^a   Cuevas, Carmen ^b   Hidalgo, Manuel ^c   Galmarini, Carlos María ^b   Allavena, Paola ^d   Avilés, Pablo ^b   Mangues, Ramón ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b PHARMAMAR S A   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Gemcitabine; Lurbinectedin; PDA mouse models; Synergism; Tumor associated macrophage depletion

Indexed keywords

CASPASE 3; CYTIDINE DEAMINASE; GAMMA HISTONE H2AX; GEMCITABINE; LURBINECTEDIN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; CARBOLINE DERIVATIVE; DEOXYCYTIDINE; FUSED HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; MACROPHAGE; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARBOLINES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MACROPHAGES; MICE, NUDE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008330507     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.026369     Document Type: Article

References (28)

1. Allavena, P. and Mantovani, A. (2012). Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 167, 195-205
2. Allavena, P., Germano, G., Belgiovine, C., D'Incalci, M. and Mantovani, A. (2013). Trabectedin: a drug from the sea that strikes tumor-associated macrophages. Oncoimmunology 2, e24614
3. Azria, D. and Lemanski, C. (2014). Intraoperative radiotherapy for breast cancer. Lancet 383, 578-581
4. Bueren-Calabuig, J. A., Giraudon, C., Galmarini, C. M., Egly, J. M. and Gago, F. (2011). Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res. 39, 8248-8257
5. Chou, T.-C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681
6. Di Caro, G., Cortese, N., Castino, G. F., Grizzi, F., Gavazzi, F., Ridolfi, C., Capretti, G., Mineri, R., Todoric, J., Zerbi, A. et al. (2016). Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 65, 1710-1720
7. Galmarini, C. M., Mackey, J. R. and Dumontet, C. (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3, 415-424
8. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F. et al. (2013). Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249-262
9. Hamilton, G., Rath, B. and Ulsperger, E. (2015). How to target small cell lung cancer. Oncoscience 2, 684-692
10. Heusinkveld, M. and van der Burg, S. H. (2011). Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 16, 209-216
11. Kübler, K., Ayub, T. H., Weber, S. K., Zivanovic, O., Abramian, A., Keyver-Paik, M. D., Mallmann, M. R., Kaiser, C., Serçe, N. B, Kuhn, W. et al. (2014). Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol. Oncol. 135, 176-183
12. Leal, J. F. M., Martínez-Díez, M., García-Hernández, V., Moneo, V., Domingo, A., Bueren-Calabuig, J. A., Negri, A., Gago, F., Guillén-Navarro, M. J., Avilés, P. et al. (2010). PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br. J. Pharmacol. 161, 1099-1110
13. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J. and Harris, A. L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 15, 4625-4629
14. Mah, L.-J., Orlowski, C., Ververis, K., El-Osta, A. and Karagiannis, T. C. (2011). Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: applications to radionuclide therapy employing auger electron-emitting isotopes. Curr. Radiopharm. 4, 59-67
15. Mielgo, A. and Schmid, M. C. (2013). Impact of tumour associated macrophages in pancreatic cancer. BMB Rep. 46, 131-138
16. Mini, E., Nobili, S., Caciagli, B., Landini, I. and Mazzei, T. (2006). Cellular pharmacology of Gemcitabine. Ann. Oncol. 17 Suppl. 5, v7-v12
17. Morgan, M. A., Meirovitz, A., Davis, M. A., Kollar, L. E., Hassan, M. C. and Lawrence, T. S. (2008). Radiotherapy combined with Gemcitabine and oxaliplatin in pancreatic cancer cells. Transl. Oncol. 1, 36-43
18. Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A. and Bradding, P. (2011). The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS ONE 6, e21874
19. Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L. and Alley, M. C. (1997). Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (ed. B. A. Teicher), pp. 101-125 New Jersey: Humana Press
20. Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J. M., Meissner, W., Krause, M., Schwörer, A.-M., Wagner, U., Müller-Brüsselbach, S. et al. (2014). Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134, 32-42
21. Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C. M., García-Fernández, L. F., Cuevas, C., Allavena, P., Erba, E. et al. (2013). Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int. J. Cancer 133, 2024-2033
22. Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., lacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H. et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661
23. Soares, D. G., Machado, M. S., Rocca, C. J., Poindessous, V., Ouaret, D., Sarasin, A., Galmarini, C. M., Henriques, J. A. P., Escargueil, A. E. and Larsen, A. K. (2011). Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol. Cancer Ther. 10, 1481-1489
24. Soares, D. G., Larsen, A. K. and Escargueil, A., E. (2012). The DNA damage response to monofunctional anticancer DNA binders. Drug Discov. Today 9, 59-67
25. Sugimura, K., Miyata, H., Tanaka, K., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K., Takiguchi, S., Mori, M. and Doki, Y. (2015). High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J. Surg. Oncol. 111, 752-759
26. Tang, X. (2013). Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 332, 3-10
27. Vidal, A., Muñoz, C., Guillén, M.-J., Moretó, J., Puertas, S., Martínez-Iniesta, M., Figueras, A., Padullés, L., García-Rodriguez, F. J., Berdiel-Acer, M. et al. (2012). Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin. Cancer Res. 18, 5399-5411
28. Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J. and Gil, Z. (2014). Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 33, 3812-3819